Peptide Tools for Immunotherapy (Cell Therapy)

About Immunotherapy (Cell Therapy)

Cellular therapy (also called cell therapy or cytotherapy) aims to treat or prevent disease by injecting living cells into the patient (e.g. cancer treatment). There are multiple strategies that differ by the cell type or the method used. Examples include types of cell therapy like allogeneic cell therapy, embryonic stem cell therapy, or immunotherapy. Immunological cytotherapy approaches like adoptive T cell therapy (including CAR), and dendritic cell therapy as a vaccination strategy use peptides to produce different types of antigen-specific immune cells e.g. for cancer immunotherapy.

JPT's Tools for Immunotherapy:

Biomarker Discovery

Peptide Biomarker Discovery

Specific T-and B-cell epitopes can be used as markers for early diagnosis,  immune monitoring, and patient stratification e.g. for cancer immunotherapy but may also help to identify new targets within the immune system for immunotherapy. JPT Peptide Technologies provides the largest variety of peptide based technologies for systematic, deep (proteome spanning) and high resolution discovery of epitopes. Due to our fast and cost efficient peptide synthesis strategies, sequence diversity (splice variants, mutations etc.) and post-translational modifications can be fully covered.

PepTrack™ Peptide Libraries for T-Cell Assays

Our customized peptide libraries with flexible layout and specifications are optimized for the use in T-cell assays such us ELISPOT and intra cellular cytokine staining. 
> PepTrack™ Peptide Libraries Product Page

Matrix Peptide Pools & PepMixes™

PepMix™ peptide pools spanning entire antigens are highly efficient tool to identify immune relevant antigens. Our custom designed 2D and 3D matrix pools enable antigen spanning T-cell epitope discovery at a minimum number of assays and saving precious patient samples. The validated pooling strategy ensures the presence of all peptides in a pool with guaranteed purity for each peptide.
> PepMix™ Peptide Pools Product Page

PepStar™ Peptide Microarrays

Our customized peptide microarrays for profiling of cancer specific samples or antibodies, detection of epitopes and epitope spreading and vaccine target identification. Peptide microarrays can display overlapping peptide scans through antigens, or selected any other peptide sequences. You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer a comprehensive assay and analysis service with your samples!
> PepStar™ Peptide Microarrays Product Page

SpikeMix™ – Peptide Standards for Mass Spectrometry based Proteomics

JPT offers pools of proteotypic peptides for the detection and relative quantification of relevant antigens  and immunodominant epitopes. The peptide pools incorporate stable isotope labeled peptides for use in mass spectrometry-based MRM assays.
> SpikeMix™ Product Page

Cell Therapy

Adoptive T-cell Immunotherapy

Antigen-specific T cells for cell therapies are generated by the ex vivo stimulation of donor PBMCs with an antigen, frequently presented through autologous activated dendritic cells. JPT’s synthetic PepMix™ Peptide Pools have been shown to be an effective tool for the generation of antigen-specific CD4+ and CD8+ T-cells, providing both helper and cytotoxic T cells. For clinical applications, we developed GxP peptides and peptide pools specifically for the ex vivo generation of cells for adoptive transfer in humans. JPT provides individual peptides, mixed epitope collections or overlapping peptide pools that span the complete antigen sequence. 

GxP Peptides & Pools

JPT’s GxP peptides and peptide pools are high quality synthetic reagents produced in a tightly regulated environment. Production of GxP peptides is regulated beyond ISO 9001:2015 regulations for the stringent product requirements of immunotherapy as well as vaccine and drug development. Thus, the resulting GxP peptides, and GxP peptide pools, have been approved for specific clinical applications.
> GxP Peptides & Pools Product Page

Immune Monitoring

Monitoring of Immune Responses

JPT’s immune system monitoring tools and services for high resolution profiling of cellular and humoral immune response target specific antigens or antigen families. This allows monitoring of individual epitope patterns as well as epitope spreading and address natural sequence diversity, mutations and post-translational modifications that occur in cancer cells and different types of viruses.
The combination of technical and bioinformatic knowledge provides efficient epitope resolved profiling of cellular immune responses that can be correlated to clinical data.

Cellular Immune Response Profiling

PepMix™ Peptide Pools

Our widely used PepMixes™ are available in a large variety of off-the-shelf peptide pools (e.g. for EBV, HCMV, Adenovirus, BKV, HHV6 and tumor associated antigens) or tailored for your specific application and antigen. We also offer a wide variety of standardization and control pools such as CEF Pools and HCMV (pp65).
> PepMix™ Peptide Pools Product Page

MHC Multimers for Detection of Antigen-Specific T cells

MHC Multimers are used for detection, enumeration and isolation of antigen-specific T cells in fluid cell samples (PBMC, blood) by flow cytometry.
> MHC Multimers Product Page

Humoral Immune Response Profiling

PepStar™ Peptide Microarrays

Our customized peptide microarrays profiling of cancer specific samples or antibodies, detection of epitopes and epitope spreading and vaccine target identification. Our peptide microarrays display overlapping peptide scans through antigens, or selected amino acid sequences. You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
> PepStar™ Peptide Microarrays Product Page

Selected References for Immunotherapy


"Low Dose Gemcitabine-loaded Lipid Nanocapsules Target Monocytic Myeloid-derived Suppressor Cells and Potentiate Cancer Immunotherapy"
Sasso et al., Biomaterials (2016)
"Specific Cytotoxic T-cell Immune Responses Against Autoantigens Recognized by Chronic Lymphocytic Leukaemia Cells"
Zaleska et al., Br J Haematol. (2016) - PMID: 27097566
"Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation"
Pietersma et al., J Clin Cell Immunol (2015)
"Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions"
Freimüller et al., Cytotherapy (2015) – PMID: 25866178
"A Single Exercise Bout Enhances the Manufacture of  Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy"
Spielmann et al., Sci Rep (2016) - PMID: 27181409
"Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy"
Lam et al., Molecular Therapy (2015) - PMID: 25366030
"Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir"
Sung et al., Journal of Infectious Diseases (2015) - PMID: 25589335
"Ex vivo Expansion of Human T cells for Adoptive Immunotherapy Using the Novel Xeno-free CTS Immune Cell Serum Replacement"
Smith et al., Clinical & Translational Immunology (2015) - PMID: 25671129
"A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma"
Krishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625
"The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial"
Geldenhuys et al., Vaccine (2015) - PMID: 26048780
"Identification of Novel Antiacetylated Vimentin Antibodies in Patients with Early Inflammatory Arthritis"
Juarez et al., Ann Rheum Dis (2015)

> More references

 

 

Selected Testimonials for Immunotherapy


"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."

Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA.

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines.  Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service.  JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations."
Benedetto Farsaci, National Cancer Institute, NIH, Bethesda, MD, USA

"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for  adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized  PepMix™ Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency."
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

> More testimonials

Selected Application Notes for Immunotherapy

Peptide-stimulated Expansion of Virus-specific T cells for Preventative Treatment After Allogeneic Stem Cell Transplantation
Gary et. al, Apllication Note (2015)
PepMix™ Peptide Pools for Clinical Applications
Keirnan et al., Application Note (2012
)
Qualification and Use of Peptide Libraries for Clinical Trial Immunomonitoring

Cox et al., Application Note (2013)

More application notes

Stay in touch and be the first to receive the latest news!